Transitioning Multiple Myeloma Care from Academic to Community Settings

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

EP: 7.Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025

EP: 8.Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma

EP: 9.Exploring Combination Bispecific Strategies in Multiple Myeloma with Talquetamab and Teclistamab from RedirecTT-1 Trial

EP: 10.Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma

EP: 11.Role of Antibody-Drug Conjugates in Multiple Myeloma

EP: 12.Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

Now Viewing

EP: 13.Transitioning Multiple Myeloma Care from Academic to Community Settings

EP: 14.Closing Perspectives and Future Directions in Multiple Myeloma Care

In this episode, experts discuss the importance of effectively transitioning patients receiving bispecific antibodies from academic centers to community practices. Panelists emphasize that access and equity remain central challenges, particularly for patients who live far from major cancer centers. They note that although initiation of therapy and management of early toxicities such as cytokine release syndrome and neurotoxicity often require experienced academic teams, risk decreases significantly after the step-up phase, making community-based care both feasible and beneficial. Experts stress the need for clear communication and structured handoff processes to prevent fragmentation of care, especially regarding infection prevention, monitoring, and supportive measures like IVIG. They highlight that empowering community clinicians through education and partnerships can reduce travel burdens and improve continuity for patients. The conversation underscores that thoughtful coordination between academic and community settings is essential as bispecific therapies expand across treatment lines.